Error in Reported Baricitinib Dose in the Article by Meesilpavikkai et al (Arthritis Rheumatol, May 2019)

In the article by Meesilpavikkai et al in the May 2019 issue of Arthritis & Rheumatology (Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi‐Goutières Syndrome, a Type I Interferonopathy pages 829–831]), it was incorrectly stated that baricitinib was initiated at a daily dose of 2 mg/kg. The statement should have read “Baricitinib treatment was initiated at a daily dose of 2 mg.”